Literature DB >> 30518536

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion.

Andrew Jay Portuguese1, Brea Lipe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30518536      PMCID： PMC6290108          DOI： 10.1182/bloodadvances.2018027532

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

Review 1.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells.

Authors:  Thomas M Kitzler; Joan Papillon; Julie Guillemette; Simon S Wing; Andrey V Cybulsky
Journal:  Biochim Biophys Acta       Date:  2012-03-08

3.  Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications.

Authors:  Gregory S Hageman; Lisa S Hancox; Andrew J Taiber; Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Monte J Radeke; David Kavanagh; Anna Richards; John Atkinson; Seppo Meri; Julie Bergeron; Jana Zernant; Joanna Merriam; Bert Gold; Rando Allikmets; Michael Dean
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

4.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Authors:  Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

5.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

6.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

7.  Impairment of the ubiquitin-proteasome pathway in RPE alters the expression of inflammation related genes.

Authors:  Zhenzhen Liu; Tingyu Qin; Jilin Zhou; Allen Taylor; Janet R Sparrow; Fu Shang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

Authors:  Y Chen; M Ooi; S F Lim; A Lin; J Lee; C Nagarajan; C Phipps; Y S Lee; N F Grigoropoulos; Z Lao; S Surendran; E M Teh; Y T Goh; W J Chng; S K Gopalakrishnan
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

9.  Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment.

Authors:  Rahul Gosain; Amitoj Gill; Jacob Fuqua; Lesley H Volz; Mika R Kessans Knable; Ryan Bycroft; Sarah Seger; Rohit Gosain; Jorge A Rios; Ju-Hsien Chao
Journal:  Clin Case Rep       Date:  2017-10-09

10.  Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.

Authors:  Peter F Zipfel; Matthew Edey; Stefan Heinen; Mihály Józsi; Heiko Richter; Joachim Misselwitz; Bernd Hoppe; Danny Routledge; Lisa Strain; Anne E Hughes; Judith A Goodship; Christoph Licht; Timothy H J Goodship; Christine Skerka
Journal:  PLoS Genet       Date:  2007-02-01       Impact factor: 5.917
View more
  9 in total

1.  Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.

Authors:  Eleni Gavriilaki; Dimitra Dalampira; Foteini Theodorakakou; Christine-Ivy Liacos; Nikolaos Kanellias; Evangelos Eleutherakis-Papaiakovou; Evangelos Terpos; Maria Gavriatopoulou; Evgenia Verrou; Theodora Triantafyllou; Aggeliki Sevastoudi; Evaggelia-Evdoxia Koravou; Tasoula Touloumenidou; Christos Varelas; Apostolia Papalexandri; Ioanna Sakellari; Meletios A Dimopoulos; Efstathios Kastritis; Eirini Katodritou
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 2.  Treatment and disease-related complications in multiple myeloma: Implications for survivorship.

Authors:  Rajshekhar Chakraborty; Navneet S Majhail
Journal:  Am J Hematol       Date:  2020-03-13       Impact factor: 10.047

3.  Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.

Authors:  Leonardo Caroti; Giuseppe Cestone; Lorenzo Di Maria; Marco Allinovi; Vicenzo Li Marzi; Sergio Serni; Calogero Lino Cirami
Journal:  Clin Nephrol Case Stud       Date:  2021-05-25

4.  An Update in Drug-Induced Thrombotic Microangiopathy.

Authors:  Thomas Chatzikonstantinou; Maria Gavriilaki; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  Front Med (Lausanne)       Date:  2020-05-22

5.  Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.

Authors:  Michael Rassner; Rebecca Baur; Andreas Mackensen; Monika Engelhardt; Ralph Wäsch; Mario Schiffer; Johanna Schneider
Journal:  BMC Nephrol       Date:  2021-01-18       Impact factor: 2.388

6.  Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.

Authors:  Odianosen Eigbire-Molen; Daniela Hermelin; Douglas Blackall
Journal:  J Med Cases       Date:  2022-06-11

Review 7.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

8.  Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.

Authors:  Piotr Kozlowski; Klodia Kameran Behnam; Bertil Uggla; Maria Åström
Journal:  Eur J Haematol       Date:  2020-03-15       Impact factor: 2.997

9.  Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.

Authors:  Despina Fotiou; Maria Roussou; Charikleia Gakiopoulou; Erasmia Psimenou; Maria Gavriatopoulou; Magdalini Migkou; Nikolaos Kanellias; Ioanna Dialoupi; Evangelos Eleutherakis-Papaiakovou; Stavroula Giannouli; Christina Delavinia; Kostantinos Efstathiou; Sofoklis Kontogiannis; Evangelos Terpos; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Blood Cancer J       Date:  2020-11-03       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.